TBXT and hepatocellular carcinoma: As the hepatitis B virus (HBV) genetic fragments can integrate into the chromosomes of liver cells during chronic infection, TCR-T therapy can target HBV antigens in HCC cells, making TCR-T therapy particularly advantageous in HBV-related HCC (116).